Key celiac disease companies such as Takeda, Sanofi, Entero Therapeutics ... and its head license with the Massachusetts Institute of Technology. In January 2024, Calypso Biotech BV announced that it ...

Key celiac disease companies such as Takeda, Sanofi, Entero Therapeutics ... and its head license with the Massachusetts Institute of Technology. In January 2024, Calypso Biotech BV announced that it ...

Sanofi is one of the leading companies in ... The firms have also invited the Joslin Diabetes Center in Boston, Massachusetts to be a partner in the venture. It is the world's largest diabetes ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

A study in the Journal of the American Chemical Society reports steps toward making inhalable mRNA medicines a possibility.

Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity M ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

A groundbreaking study introduces stable inhalable mRNA treatment using nanoparticles that hold up during nebulization, ...

Massachusetts-based Kymera has retained the ... The $150 million gives Sanofi rights to develop its small molecule IRAK4 protein degraders in inflammation and immunology indications, and a ...

Dr. Meijing Wu is described by friends and colleagues as a distinguished biostatistician and “a kind and generous friend who ...

Interestingly, since emicizumab was approved, new activated FVIII mimetic bispecific antibodies have been developed, such as BS-027125 (Bioverativ, Waltham, MA, USA)39 and Mim8 ... the Humanitarian ...